The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 10, 2006
Filed:
Jul. 26, 2001
David Botstein, Belmont, CA (US);
Patrick O. Brown, Stanford, CA (US);
Charles M. Perou, Carrboro, NC (US);
Brian Ring, Foster City, CA (US);
Douglas Ross, San Francisco, CA (US);
Rob Seitz, Hampton Cove, AL (US);
Jan Matthijs Van DE Rijn, La Henda, CA (US);
David Botstein, Belmont, CA (US);
Patrick O. Brown, Stanford, CA (US);
Charles M. Perou, Carrboro, NC (US);
Brian Ring, Foster City, CA (US);
Douglas Ross, San Francisco, CA (US);
Rob Seitz, Hampton Cove, AL (US);
Jan Matthijs van de Rijn, La Henda, CA (US);
Applied Genomics, Inc., Sunnyvale, CA (US);
Board of Trustees of Leland Stanford Junior University, Stanford, CA (US);
Abstract
The invention provides a variety of reagents for use in the diagnosis and management of breast cancer. The invention utilizes cDNA microarray technology to identify genes whose expression profile across a large group of tumor samples correlates with that of cytokeratin 5 and cytokeratin 17, markers for basal cells of the normal mammary lactation gland. The invention demonstrates that tumors that express cytokeratin 5/6 and/or 17 have a poor prognosis relative to tumors overall. The invention provides basal marker genes and their expression products and uses of these genes for diagnosis of breast cancer and for identification of therapies for breast cancer. In particular, the invention provides basal marker genes including cadherin3, matrix metalloproteinase 14, and cadherin EGF LAG seven-pass G-type receptor 2. The invention provides antibodies to the polypeptides expressed by these genes and methods of use thereof.